He aha kāu e pono ai e ʻike e pili ana i ka palmitoylethanolamide (PEA)?

ʻO Palmitoylethanolamide (PEA) kahi amide momona momona kūlohelohe i huki i ka manaʻo no kona mau pono olakino. Loaʻa kēia hui i nā ʻiʻo like ʻole ma ke kino, a hōʻike ka noiʻi e hiki i ka palmitamideethanol (PEA) ke hōʻoluʻolu i ka mumū, hoʻemi i ka ʻeha, a hiki ke hoʻolaha i ke olakino ʻōpū a hoʻopaneʻe i ka ʻelemakule. Loaʻa paha iā ia nā pono olakino like ʻole. E ʻimi ana ka ʻike ma lalo nei i nā pono olakino o ka palmitoylethanolamide (PEA), pehea e hana ai ma ke kino kanaka, a pehea e loaʻa ai ka palmitoylethanolamide (PEA) kiʻekiʻe.

He aha ka palmitoylethanolamide (PEA)?

ʻO Palmitoylethanolamide (PEA) he hui like me ka endocannabinoid i ʻike ʻia no kona mau waiwai analgesic mau a me nā waiwai anti-inflammatory. Ma waho aʻe o ka synthesized ʻia e ke kino, loaʻa ka PEA i nā ʻano meaʻai like ʻole e like me: tīhi, yolks hua manu, ʻiʻo, waiū, pīnati, soy lecithin.

Ua ʻike anei ʻoe? Ke hālāwai ke kino me nā mea hoʻoluhi, e like me ka ʻeha a i ʻole ka mumū, hoʻoponopono nā pae PEA e mālama i ka homeostasis cellular.

Pehea ka hopena o ka palmitoylethanolamide i ke kino o ke kanaka?

ʻAʻole maopopo loa i nā kānaka ʻepekema ke ʻano o ka hana o ka palmitoylethanolamide. Eia nō naʻe, ua hele lōʻihi mākou, mahalo iā Polofesa Rita Levi-Montalcini, nāna i wehewehe i ka hana maʻamau o ka palmitoylethanolamide i ka makahiki 1992-1996. Mai ia manawa, ua hoʻomau ʻo ia i ke aʻo ʻana i nā hopena o ka palmitoylethanolamide i ka ʻeha neuropathic a me nā maʻi allergies.

Hiki i ka Palmitoylethanolamide ke lawe mai i ʻehā mau pono olakino nui i ke kanaka:

●Hoʻomaha i ka pane mumū.

●E hōʻemi i ka hoʻāla ʻana o nā pūnaewele mast (allergy).

● Hoʻoikaika i ka hana o ka ʻōnaehana hemp endogenous.

●Hoʻoulu i nā mea loaʻa kikoʻī i loko o ke kino.

Pehea e hoʻohana ai ʻo PEA i kona hopena anti-inflammatory a me analgesic?

ʻO nā pono olakino o PEA e pili ana i nā hopena ma nā pūnaewele pale e kāohi ana i ka mumū, ʻoi aku hoʻi i ka lolo. Hiki i ka PEA ke kōkua i ka hōʻemi ʻana i ka hana ʻana o nā mea mumū. Eia nō naʻe, hana nui ka PEA ma nā mea loaʻa ma nā pūnaewele, nāna e kāohi i nā ʻano like ʻole o ka hana o ke kelepona. Ua kapa ʻia kēia mau mea loaʻa he PPAR. Hiki i ka PEA a me nā hui ʻē aʻe e kōkua ana i ka hoʻoulu ʻana i ka PPAR ke hōʻemi i ka ʻeha a hiki ke hoʻonui i ka metabolism ma ka puhi ʻana i ka momona, hoʻohaʻahaʻa i nā triglycerides serum, hoʻonui i ka serum HDL cholesterol, hoʻomaikaʻi i ka kaohi ʻana i ke kō koko, a kōkua i ka pohō kaumaha.

Nā Pōmaikaʻi o Palmitoylethanolamide

Ma muli o kona mau hopena analgesic a me nā anti-inflammatory, hōʻike ka noiʻi e hiki i ka PEA ke kōkua me nā ʻano ʻeha like ʻole, e like me fibromyalgia, sciatica, a me osteoarthritis.

1. Hoʻomaha i ka ʻeha a me ka pane mumū

He pilikia koʻikoʻi ka ʻeha mau loa e hoʻopilikia nei i nā maʻi a puni ka honua, a i ka wā e ʻelemakule ai ka heluna kanaka, e lilo kēia pilikia i mea nui aʻe. ʻO kekahi o nā hana o ka palmitoylethanolamide ʻo ia ke kōkua i ka hōʻoluʻolu ʻana i ka ʻeha a me ka mumū. Hoʻopili ka palmitoylethanolamide me nā mea loaʻa CB1 a me CB2, he mau ʻāpana koʻikoʻi o ka ʻōnaehana hemp endogenous. ʻO kēia ʻōnaehana ke kuleana no ka mālama ʻana i ka homeostasis a i ʻole ke kaulike i loko o ke kino.

Ke loaʻa kahi ʻeha a i ʻole ka pane mumū, hoʻokuʻu ke kino i nā pūhui hemp endogenous e kōkua i ka kaohi ʻana i ka pane pale. hiki i ka palmitoylethanolamide ke kōkua i ka hoʻonui ʻana i nā pae hemp endogenous i loko o ke kino, no laila e hōʻoluʻolu ai i ka ʻeha a me ka mumū.

Eia kekahi, hiki i ka palmitoylethanolamide ke hōʻemi i ka hoʻokuʻu ʻana o nā kemika mumū a hōʻemi i nā pane mumū neurological holoʻokoʻa. ʻO kēia mau hopena e hana ai i ka palmitoylethanolamide i mea hana kūpono e kōkua i ka kaohi ʻana i ka ʻeha a me nā pane mumū. Hōʻike nā haʻawina e hiki ke kūpono ka palmitoylethanolamide no ka ʻeha sciatica a me ka carpal tunnel syndrome.

2. Fibromyalgia

Manaʻo kekahi mau noiʻi e hiki i ka PEA ke kōkua i ka hōʻemi ʻana i nā hōʻailona o ka fibromyalgia, kahi maʻi neurological mau loa e hoʻoulu ai i ka ʻeha ākea. Ke hoʻohana ʻia ma ke ʻano he mea hoʻohui i nā lāʻau lapaʻau kuʻuna, hōʻemi ka ʻai ʻana o PEA i ka ikaika o ka ʻeha a hoʻomaikaʻi i ke ʻano o ke ola i ka hala ʻana o ka manawa. Wahi a kekahi noiʻi, ʻo ka lawe ʻana iā PEA no ʻekolu mahina ua hōʻemi nui i ka ʻeha i ka poʻe me ka fibromyalgia.

3. ʻEha hope

Kuhikuhi ka noiʻi mua i ka pono o PEA no ka ʻeha hope. Ua hōʻike ʻia kahi noiʻi nānā ʻana i ka makahiki 2017 ua hōʻemi hou aku ka PEA i ka nui o ka ʻeha i nā poʻe maʻi me ka maʻi ʻoki hope i hāʻule.

ʻO ka poʻe e ʻeha nei i ka sciatica, kahi ʻeha e hoʻomaka ana mai ke kua haʻahaʻa i lalo i kekahi a i ʻole nā ​​​​wāwae ʻelua, hiki ke loaʻa ka hōʻoluʻolu ma hope o ka lawe ʻana iā PEA. Ua aʻo ʻia kahi hoʻokolohua randomized, double-blind, placebo-controlled i nā hopena o ka PEA kiʻekiʻe a me ka haʻahaʻa haʻahaʻa e hoʻohālikelike ʻia me ka placebo. Ua hoʻemi ʻia ka ʻeha ma mua o 50% i ka hui kiʻekiʻe. ʻOiai ʻaʻole i hoʻokō ka PEA haʻahaʻa haʻahaʻa i ke ʻano like o ka hōʻoluʻolu ʻeha e like me ka nui o ka nui, ʻoi aku ka maikaʻi o nā dosis ʻelua ma mua o ka placebo.

4. ʻO ka ʻeha puʻuwai

He mea maikaʻi paha ka PEA no ka poʻe me ka osteoarthritis, kahi maʻi i hōʻike ʻia e ka degeneration o ke cartilage a me ka iwi hui. ʻO nā mea komo i hoʻokahi noiʻi i loaʻa iā PEA ua ʻike lākou i nā hoʻomaikaʻi koʻikoʻi ma nā helu Western Ontario a me McMaster Universities Osteoarthritis Index (WOMAC) i hoʻohālikelike ʻia me ka hui placebo. ʻO ka WOMAC kahi nīnau i hoʻolālā ʻia e loiloi i ke kūlana a me nā hōʻailona (e laʻa, ʻeha, ʻoʻoleʻa, hana kino) i nā poʻe maʻi me ka osteoarthritis kuli a me ka ʻūhā.

Ua hōʻike ʻia kekahi noiʻi e pili ana i nā poʻe maʻi me ka ʻeha temporomandibular arthritic (TMJ) e pili ana me ka osteoarthritis ua hoʻomaikaʻi nui ka hoʻohui PEA i ka ikaika o ka ʻeha ma hope o 14 mau lā i hoʻohālikelike ʻia me ka ibuprofen. Ua hōʻike ka hui i hāʻawi ʻia iā PEA no 14 mau lā i ka hoʻomaikaʻi nui ʻana i ka wehe ʻana o ka waha (kahi ana o ka hōʻoluʻolu ʻeha) ma mua o ka hui ibuprofen.

5. ʻEha neuropathic

Hōʻike nā haʻawina hihia mua a me nā hoʻāʻo holoholona e hiki i ka PEA ke kōkua me ka ʻeha neuropathic (i hoʻokumu ʻia e ka hōʻino ʻana i nā aʻalolo e lawe ana i nā leka ma waena o ka lolo a me ke kaula spinal), ʻoi aku hoʻi i ka poʻe me ka carpal tunnel syndrome, diabetic neuropathy, chemotherapy. ʻO nā kānaka me ka neuropathy peripheral, ka ʻeha pelvic mau, a me ka ʻeha e pili ana me ka hahau a me ka sclerosis maha. Pono nā hoʻokolohua lapaʻau hou aʻe e hoʻoholo i ka pono o PEA i ka hoʻoponopono ʻana i ka ʻeha neuropathic.

6. Ka ʻelemakule olakino

ʻO ka hoʻopaneʻe ʻana i ke kaʻina hana ʻelemakule kahi pahuhopu waiwai kūpono i alualu ʻia e nā ʻepekema he nui a puni ka honua. Ua manaʻo ʻia ʻo Palmitoylethanolamide he mea hoʻohui anti-aging e kōkua paha i ka pale ʻana i nā cell mai ka hōʻino oxidative, ʻo ia ke kumu nui o ka ʻelemakule.

Ke hōʻike ʻia nā pūnaewele i ka hana radical manuahi nui loa, hiki ke hana ʻia nā hopena oxidative, e alakaʻi ana i ka make ʻana o nā pūnaewele i ka wā ʻōpiopio. ʻO ka ʻai ʻana i nā meaʻai maikaʻi ʻole, ka puhi paka, a me nā mea ʻē aʻe e pili ana i ke kaiapuni e like me ka haumia o ka ea e hoʻonui pū i ka pōʻino oxidative. Hiki i ka Palmitoylethanolamide ke pale i kēia pōʻino ma ka wehe ʻana i nā radical manuahi a me ka hoʻēmi ʻana i ka pane mumū holoʻokoʻa i loko o ke kino.

Eia kekahi, ua hōʻike ʻia ka palmitoylethanolamide ethanol e hoʻoulu i ka hana ʻana o ka collagen a me nā protein ʻili koʻikoʻi ʻē aʻe. No laila, hiki iā ia ke hōʻemi i ke ʻano o nā wrinkles a me nā laina maikaʻi, e hana ana ma ke ʻano he mea pale mai loko mai o nā cell.

He mea hana i hoʻopaʻa inoa ʻia ʻo Suzhou Myland Pharm & Nutrition Inc. i hoʻolako i ka pauka Palmitoylethanolamide (PEA) kiʻekiʻe a me ka maʻemaʻe.

Ma Suzhou Myland Pharm, ua kūpaʻa mākou i ka hāʻawi ʻana i nā huahana kiʻekiʻe loa ma nā kumukūʻai maikaʻi loa. Ua hoʻāʻo pono ʻia kā mākou pauka Palmitoylethanolamide (PEA) no ka maʻemaʻe a me ka ikaika, e hōʻoiaʻiʻo ana e loaʻa iā ʻoe kahi mea hoʻohui kiʻekiʻe hiki iā ʻoe ke hilinaʻi. Inā makemake ʻoe e kākoʻo i ke olakino cellular, hoʻoikaika i kāu ʻōnaehana pale, a hoʻomaikaʻi paha i ke olakino holoʻokoʻa, ʻo kā mākou pauka Palmitoylethanolamide (PEA) ke koho kūpono loa.

Me 30 mau makahiki o ka ʻike a hoʻokele ʻia e ka ʻenehana kiʻekiʻe a me nā hoʻolālā R&D i hoʻonohonoho pono ʻia, ua hoʻomohala ʻo Suzhou Myland Pharm i nā huahana hoʻokūkū a lilo i ʻoihana hoʻohui ʻepekema ola hou, synthesis maʻamau a me nā lawelawe hana.

Eia kekahi, he mea hana i hoʻopaʻa inoa ʻia ʻo Suzhou Myland Pharm i ka FDA. He hou a he nui nā hana o nā kumuwaiwai R&D o ka hui, nā hale hana, a me nā mea hana loiloi, a hiki ke hana i nā kemika mai nā milligrams a i nā tons ma ke anakahi, a kūlike me nā kūlana ISO 9001 a me nā kikoʻī hana GMP.